Obiettivo The objective of this Apotherapy Specific Targeted Research Project proposal is to establish a European collective of international scientific excellence to combat cancer by translating basic research on key apoptotic pathways into tools which will improve the treatment and quality of life of cancer sufferers. The project will specifically aim to exploit the widespread expression of CD40, a TNF receptor family member, in human tumours and develop CD40 ligand-based modalities with high therapeutic potential and minimal side-effects. These translational studies are based on accumulating in vitro evidence suggesting that the activation of CD40 results in reduced proliferation and apoptosis induction selectively in cancer cells.The proposed STREP will develop vehicles for the efficient delivery of CD40L, such as CD40L-encapsulated liposome formulations and recombinant adenoviruses expressing CD40L and examine their in vitro and in vivo effects on tumour cell growth and metastasis. Apoptosis induced by CD40 engagement is dramatically augmented in the presence of inhibitors of the phosphoinositide 3-kinase (PI3 kinase) pathway which is frequently found activated in human tumours. The proposed STREP will expand on the development of inositol polyphosphates, novel PI3 kinase antagonists, and evaluate their in vitro and in vivo capacity to kill tumour cells and to amplify the CD40L-mediated effects on carcinoma cell growth, angiogenesis and metastasis. These studies will provide essential information for progressing the potential therapeutic strategy towards future clinical trials for the benefit of cancer sufferers. Campo scientifico medical and health sciencesclinical medicineoncologybladder cancermedical and health sciencesbasic medicinepharmacology and pharmacydrug resistance Programma(i) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Argomento(i) LSH-2005-2.2.0-2 - Modulation of apoptosis in cancer prevention and therapy Invito a presentare proposte FP6-2005-LIFESCIHEALTH-6 Vedi altri progetti per questo bando Meccanismo di finanziamento STREP - Specific Targeted Research Project Coordinatore UNIVERSITY OF CRETE Contributo UE Nessun dato Indirizzo KNOSSOU Ave.-UNIVERSITY CAMPUS 2208 HERAKLION Grecia Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato Partecipanti (7) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto UNIVERSITY COLLEGE LONDON Regno Unito Contributo UE Nessun dato Indirizzo Gower Street LONDON Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato ISTITUTO DI RICERCHE FARMACOLOGICHE "MARIO NEGRI" Italia Contributo UE Nessun dato Indirizzo Via Eritrea 62 MILANO Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato HELSINGIN YLIOPISTO Finlandia Contributo UE Nessun dato Indirizzo Yliopistonkatu 4 UNIVERSITY OF HELSINKI, HELSINKI Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato UNIVERZITA PALACKEHO V OLOMOUCI Cechia Contributo UE Nessun dato Indirizzo Krizkovskeho 8 OLOMOUC Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato UPPSALA UNIVERSITY Svezia Contributo UE Nessun dato Indirizzo Sankt Olofsgatan 10B 256 UPPSALA Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato NOVOSOM AG Germania Contributo UE Nessun dato Indirizzo Weinbergweg 22 HALLE Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato QUEEN MARY & WESTFIELD COLLEGE, UNIVERSITY OF LONDON Regno Unito Contributo UE Nessun dato Indirizzo MILE END ROAD LONDON Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato